India Positions Itself for Rare Disease Pharma Growth Amid US Tariff Exemptions
India's established pharmaceutical manufacturing base could emerge as a global hub for rare disease therapies, supported by recent United States trade exemptions and growing domestic capabilities. According to Rx4u, while conventional generic exports face sweeping new US tariffs, specialized treatments for rare conditions remain protected under zero duty provisions announced by the US Department of Commerce.
According to Federal Register, the US Department of Commerce Bureau of Industry and Security published an official notice confirming a 0% tariff rate for orphan drugs, nuclear medicines, and cell/gene therapies under Section 232. According to Business Upturn, uS tariff exemptions eliminate duty overhangs for Indian pharma exporters investing in orphan APIs, cell therapies, and radiopharmaceuticals.
Industry analysts note that while the Indian government currently provides financial support of up to fifty lakh rupees for individual rare disease treatments, cumulative annual costs for registered patients exceed nine thousand crore rupees. According to Rx4u, most rare conditions lack approved therapeutics entirely, and treatments that do exist can cost upwards of one hundred thousand dollars annually, forcing many families to rely on public crowdfunding platforms.
Manufacturing Strengths and Regulatory Pathways
According to Insight IIT Bombay, india supplies approximately 40 to 47 percent of all generic prescriptions consumed in the United States and maintains the highest concentration of US Food and Drug Administration approved manufacturing facilities outside North America. Local plants already produce advanced therapeutics such as CAR-T cell cancer therapies to international standards, demonstrating technical readiness for complex biopharmaceuticals.
According to The Hindu, regulatory mechanisms like Rule 101 of the New Drugs and Clinical Trials Rules allow medicines already approved in six specified jurisdictions, including the United States and the United Kingdom, to bypass domestic clinical trials before receiving Central Drugs Standard Control Organisation approval. Analysts argue that streamlining this pathway further could accelerate local orphan drug manufacturing.
Under the National Policy for Rare Diseases 2021, eligible patients can receive financial aid reaching up to ₹50 lakh for treatments administered exclusively in government tertiary hospitals and designated Centres of Excellence, complementing broader regulatory frameworks. According to The Hindu, additionally, the Central Government has authorized local clinical trial exemptions under Rule 101 for orphan drugs approved within designated reference nations.
Leveraging Demographic and Genetic Advantages
With a population exceeding 1.4 billion people and high rates of endogamy within specific ethnic groups, India presents a natural clinical environment for genetic research. For instance, beta-thalassemia prevalence reaches 10.5 percent in certain communities compared to a national average of 3.7 percent, while the global Indian diaspora carries distinct mutation profiles across diverse ethnicities.
According to Insight IIT Bombay, indigenous CAR-T manufacturing requires cGMP Grade B/A cleanrooms, automated closed-system bioreactors, viral vector biosafety containment, and cryogenic storage facilities. According to PMC / Orphanet Journal of Rare Diseases, the ICMR operates the hospital-based National Registry for Rare Diseases (NRRD) across national premier medical centers to gather epidemiological data on rare genetic disorders.
Experts propose establishing structured collaboration models where local patient groups and research institutions partner with multinational drug developers. Such frameworks aim to ensure that domestic participants function as beneficiaries of resulting therapeutics rather than serving exclusively as data sources.
Policy Interventions and Pricing Models
To foster local production without relying solely on subsidies, policy proposals include Production-Linked Incentive schemes, tax exemptions for orphan drug development, technology transfers through national laboratories, and Advance Market Commitments. Proponents suggest that government procurement through Centres of Excellence and Jan Aushadhi Kendras could secure long-term demand.
benefit-sharing frameworks could allow India to determine domestic pricing for the Global South while permitting standard commercial pricing in high-income markets. These measures mirror global discussions on equitable access, positioning the country to capture a major share of the emerging orphan drug economy as global pharmaceutical firms seek alternative manufacturing partners.
Next Steps and Implementation Milestones
Implementation depends on whether policymakers establish dedicated financial incentives and advance market commitments for domestic orphan drug manufacturing before upcoming trade adjustments take full effect.